6th December 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

JB pharma reduces the price of Critical Heart Failure medicine by 50%

Indian Pharma company JB Chemicals & Pharmaceuticals Ltd. (JB Pharma), has surprisingly reduced the price of its critical heart failure drug “Azmarda” by 50%. After reduction, Azmarda (50 mg) will be available at ₹39.6 per tablet compared to ₹78 per tablet earlier.

HC stays order enforcing penalty on Sun Pharma worth ₹10 Lakhs

The Delhi High Court in a recent order has stayed its order made in November that imposed a fine of ₹10 Lakhs on Sun Pharmaceuticals over alleged concealment of facts in a trademark case. The order has been stayed till 27th March 2023.

HC supported order allowing Natco Pharma to market Insecticide CTPR

The Delhi High Court on Monday supported its order that allowed Natco Pharmaceuticals to market an insecticide named Chlorantraniliprole (CTPR), saying it does not infringe on the United States agrochemical company’s patent.

MapMyGenome launches pharmacogenomics solution MedicaMap

MapMyGenome is a preventive genomics company that launched its pharmacogenomics solution ‘MedicaMap’ on Sunday. This spectacular technology analyzes an individual’s response to medicines based on their genetic makeup.

Clovis Oncology defaults on loan and further agrees to restrict the use of Rubraca

Clovis Oncology has defaulted on a loan after failing to make an interest payment that was due Nov. 1—with a 30-day grace period to Dec. 1. Moreover, the company at FDA’s request has agreed to restrict the use of its cancer drug ‘Rubraca’ to those whose tumors have BRCA mutations.

Backed by Pfizer, Mediar Therapeutics attracts in another pharma giant as investor

Originating from Mass General and Brigham and Women’s Hospital, a biotech focused on treating fibrosis has received $31,761,186 in its latest funding round, which includes 17 investors, according to an SEC filing.

Syndax’s revumenib gets US FDA's breakthrough therapy status

Syndax Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, declared that the US FDA has granted the Breakthrough Therapy Designation (BTD) for ‘revumenib’ indicated for adult and pediatric patients with relapsed or refractory (R/R) acute leukemia harboring a KMT2A rearrangement.

Update profile

Please update your profile to keep using the website

Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?